Levosulpiride
Levosulpiride, sold under the brand name Neoprad is a substituted benzamide antipsychotic,[1] reported to be a selective antagonist of dopamine D2 receptor activity[2] on both central and peripheral levels. It is an atypical neuroleptic and a prokinetic agent.[2] Levosulpiride is also claimed to have mood elevating properties.
Clinical data | |
---|---|
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C15H23N3O4S |
Molar mass | 341.43 g·mol−1 |
| |
(what is this?) (verify) |
Chemically, it is the (S)-(−)-enantiomer of sulpiride.
Uses
Levosulpiride is used in the treatment of:
- psychoses
- particularly negative symptoms of schizophrenia
- anxiety disorders
- dysthymia
- vertigo
- dyspepsia
- irritable bowel syndrome
- premature ejaculation.
Levosulpiride is not currently licensed for treatment of premature ejaculation in the UK or other European countries.[3]
Side effect
Side effects include amenorrhea, gynecomastia, galactorrhea, changes in libido, and neuroleptic malignant syndrome.[4] In the U.S., as of 2013 only one case of adverse reaction to levosulpiride had been recorded on the FDA Adverse Event Reporting System Database.[3] A case of rapid onset resistant dystonia caused by low dose levosulpiride was reported in India.[5]
Mechanism of action
In contrast to most other neuroleptics which block both dopamine D1 and D2 receptors, sulpiride is more selective and acts primarily as a dopamine D2 antagonist. Sulpiride appears to lack effects on norepinephrine, acetylcholine, serotonin, histamine, or gamma-aminobutyric acid (GABA) receptors.[6]
Pharmacodynamics
Sulpiride is a substituted benzamide derivative and a selective dopamine D2 antagonist with antipsychotic and antidepressant activity. Other benzamide derivatives include metoclopramide, tiapride, and sultopride.[6]
References
- "Levosulpiride - S-(-)-Sulpiride". Generon. Retrieved 2016-08-31.
- "Levosulpiride". Stratech Scientific Ltd. Retrieved 2016-08-31.
- Poluzzi E, Raschi E, Koci A, Moretti U, Spina E, Behr ER, et al. (June 2013). "Antipsychotics and torsadogenic risk: signals emerging from the US FDA Adverse Event Reporting System database". Drug Safety. 36 (6): 467–79. doi:10.1007/s40264-013-0032-z. PMC 3664739. PMID 23553446.
- "Levosulpiride drug information". DrugsUpdate India.
- Naskar S, Nath K (January 2007). "Rapid onset resistant dystonia with low dose of Levosulpiride". British Journal of Psychiatry. 190 (1): 81. doi:10.1192/bjp.190.1.81a.
- "Sulpiride". DrugBank. DB00391.